The FDA has accepted AbbVie's supplemental Biologics License Application (sBLA) for BOTOX Cosmetic to treat masseter muscle prominence, the first neurotoxin indication for this specific aesthetic concern. The acceptance signals FDA agreement that the data package supports review, moving the indication toward a potential approval decision.
Regulatory
FDA Accepts BOTOX Cosmetic sBLA for Masseter Prominence
AbbVie's BOTOX Cosmetic wins FDA acceptance for masseter muscle prominence—first and only neurotoxin indication if approved.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
First neurotoxin indication for masseter prominence; exclusive if approved.
Masseter prominence—often called "square jaw" or mandibular hypertrophy—is a growing aesthetic category, particularly among younger patients seeking jawline refinement without surgery. If approved, BOTOX Cosmetic will own this indication exclusively among toxins. For practices, this represents a new revenue stream and a competitive advantage for AbbVie in the toxin portfolio. Expect marketing support and potential Allē rebate incentives tied to this indication once approved. Practices should begin training staff on patient selection and injection technique now.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.